Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ludwig Merker

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
MMW Fortschritte Der Medizin|April 27, 2021
[Nephropathy in diabetes]Ludwig Merker
Advances in Therapy|May 13, 2015
Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira)Javier Morales, Ludwig Merker
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|January 23, 2023
Nephropathy in DiabetesLudwig Merker, Thomas Ebert, Martina Guthoff, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|May 6, 2025
Nephropathy in DiabetesLudwig Merker, Thomas Ebert, Erwin Schleicher, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|January 4, 2021
Nephropathy in DiabetesLudwig Merker, Bernd-Walter Bautsch, Thomas Ebert, et al.
Diabetes Care|August 22, 2013
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trialHans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, et al.
Diabetes Care|April 12, 2014
Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trialHans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, et al.
Cardiovascular Diabetology|December 25, 2015
Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trialMichael Roden, Ludwig Merker, Anita Vedel Christiansen, et al.
Diabetes Research and Clinical Practice|September 2, 2015
Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetesHans-Ulrich Haering, Ludwig Merker, Anita Vedel Christiansen, et al.
Clinical Therapeutics|July 4, 2015
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes MellitusChristopher S Kovacs, Veeraswamy Seshiah, Ludwig Merker, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
MMW Fortschritte Der Medizin|April 27, 2021
[Nephropathy in diabetes]Ludwig Merker
Advances in Therapy|May 13, 2015
Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira)Javier Morales, Ludwig Merker
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|January 23, 2023
Nephropathy in DiabetesLudwig Merker, Thomas Ebert, Martina Guthoff, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|May 6, 2025
Nephropathy in DiabetesLudwig Merker, Thomas Ebert, Erwin Schleicher, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|January 4, 2021
Nephropathy in DiabetesLudwig Merker, Bernd-Walter Bautsch, Thomas Ebert, et al.
Diabetes Care|August 22, 2013
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trialHans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, et al.
Diabetes Care|April 12, 2014
Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trialHans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, et al.
Cardiovascular Diabetology|December 25, 2015
Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trialMichael Roden, Ludwig Merker, Anita Vedel Christiansen, et al.
Diabetes Research and Clinical Practice|September 2, 2015
Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetesHans-Ulrich Haering, Ludwig Merker, Anita Vedel Christiansen, et al.
Clinical Therapeutics|July 4, 2015
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes MellitusChristopher S Kovacs, Veeraswamy Seshiah, Ludwig Merker, et al.
Pageof 2